We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda Gets FDA Nod for Combo Lung Cancer Drug and Genetic Targeting Test
Takeda Gets FDA Nod for Combo Lung Cancer Drug and Genetic Targeting Test
The FDA has granted accelerated approval to Takeda Pharmaceutical’s Exkivity (mobocertinib), the first oral tyrosine kinase inhibitor for nonsmall-cell lung cancer (NSCLC) associated with certain gene mutations that are detected using a proprietary gene-sequencing test.